Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Fresh Tracks Therapeutics Inc FRTX

Healthcare Biotechnology
Fresh Tracks Therapeutics, Inc. is not engaged in any business activities. The Company is in the process of dissolution.

Recent & Breaking News (GREY:FRTX)

Vical to Present at the 28th Annual ROTH Conference

GlobeNewswire March 9, 2016

Vical Announces News Release and Conference Call Schedule for Fourth Quarter 2015 Financial Results

GlobeNewswire March 7, 2016

Vical Initiates Phase 1 Trial of Novel Antifungal Compound VL-2397

GlobeNewswire March 7, 2016

FDA Grants Vical Orphan Drug Designation for VL-2397 for the Treatment of Invasive Aspergillosis

GlobeNewswire January 6, 2016

Vical Appoints Dr. Thomas Shenk to Board of Directors

GlobeNewswire December 21, 2015

Vical to Present at the Stifel Healthcare Conference 2015

GlobeNewswire November 11, 2015

Vical Reports Third Quarter 2015 Financial Results and Progress in Key Development Programs

GlobeNewswire October 29, 2015

Vical Announces News Release and Conference Call Schedule for Third Quarter 2015 Financial Results

GlobeNewswire October 22, 2015

Vical to Present Preclinical Data at ICAAC 2015 Meeting for Its Novel Antifungal Drug Candidate VL-2397

GlobeNewswire September 15, 2015

Vical to Present at the Rodman & Renshaw 17th Annual Global Investment Conference

GlobeNewswire September 3, 2015

FDA Grants Qualified Infectious Disease Product (QIDP) Designation to VL-2397, Vical's Antifungal Product Candidate

GlobeNewswire August 19, 2015

Vical Reports Second Quarter 2015 Financial Results and Progress in Key Development Programs

GlobeNewswire July 30, 2015

Vical Announces News Release and Conference Call Schedule for Second Quarter 2015 Financial Results

GlobeNewswire July 23, 2015

Vical Announces News Release and Conference Call Schedule for Second Quarter 2015 Financial Results

GlobeNewswire July 23, 2015

Vical Reports Top-Line Results From Phase 1/2 Trial of Therapeutic Genital Herpes Vaccine

GlobeNewswire June 22, 2015

Vical Announces Completion of Enrollment in Phase 2 Clinical Trial of Investigational CMV Vaccine in Kidney Transplant Recipients

GlobeNewswire May 21, 2015

Vical Reports First Quarter 2015 Financial Results and Progress in Key Development Programs

GlobeNewswire May 8, 2015

Vical Announces News Release and Conference Call Schedule for First Quarter 2015 Financial Results

GlobeNewswire May 1, 2015

Vical to Manufacture HIV Vaccines for Clinical Evaluation by Public-Private Partnership Initiative

GlobeNewswire April 22, 2015

Vical Announces Presentation of Preclinical Data for Congenital CMV DNA Vaccine at International Conference

GlobeNewswire April 21, 2015